Voyager Therapeutics Gross Profit vs. Total Asset

VYGR Stock  USD 5.75  0.06  1.05%   
Based on Voyager Therapeutics' profitability indicators, Voyager Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Voyager Therapeutics' ability to earn profits and add value for shareholders.
For Voyager Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Voyager Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Voyager Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Voyager Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Voyager Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
To learn how to invest in Voyager Stock, please use our How to Invest in Voyager Therapeutics guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Voyager Therapeutics. If investors know Voyager will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Voyager Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.66
Revenue Per Share
2.953
Quarterly Revenue Growth
4.338
Return On Assets
0.0157
Return On Equity
0.1022
The market value of Voyager Therapeutics is measured differently than its book value, which is the value of Voyager that is recorded on the company's balance sheet. Investors also form their own opinion of Voyager Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Voyager Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Voyager Therapeutics' market value can be influenced by many factors that don't directly affect Voyager Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Voyager Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Voyager Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Voyager Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Voyager Therapeutics Total Asset vs. Gross Profit Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Voyager Therapeutics's current stock value. Our valuation model uses many indicators to compare Voyager Therapeutics value to that of its competitors to determine the firm's financial worth.
Voyager Therapeutics is rated third in gross profit category among its peers. It is rated fifth in total asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Voyager Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Voyager Total Asset vs. Gross Profit

Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Voyager Therapeutics

Gross Profit

 = 

Revenue

-

Cost of Revenue

 = 
(19.86 M)
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

Voyager Therapeutics

Total Asset

 = 

Tangible Assets

+

Intangible Assets

 = 
351.28 M
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.

Voyager Total Asset Comparison

Voyager Therapeutics is currently under evaluation in total asset category among its peers.

Voyager Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Voyager Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Voyager Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Voyager Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Voyager Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. Voyager Therapeut operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 101 people.

Voyager Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Voyager Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Voyager Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Voyager Therapeutics' important profitability drivers and their relationship over time.

Use Voyager Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Voyager Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Voyager Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Voyager Therapeutics Pair Trading

Voyager Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Voyager Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Voyager Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Voyager Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Voyager Therapeutics to buy it.
The correlation of Voyager Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Voyager Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Voyager Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Voyager Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Voyager Therapeutics position

In addition to having Voyager Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Broad Equity ETFs Thematic Idea Now

Broad Equity ETFs
Broad Equity ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Equity ETFs theme has 483 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Equity ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Voyager Stock Analysis

When running Voyager Therapeutics' price analysis, check to measure Voyager Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyager Therapeutics is operating at the current time. Most of Voyager Therapeutics' value examination focuses on studying past and present price action to predict the probability of Voyager Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyager Therapeutics' price. Additionally, you may evaluate how the addition of Voyager Therapeutics to your portfolios can decrease your overall portfolio volatility.